Transvaginal (pelvic) mesh

Over the past two decades there has been a rise in the prevalence and severity of problems attributed to transvaginal (pelvic) mesh implants.

The Australian Commission on Safety and Quality in Health Care, in consultation with key stakeholders, has examined the safety and clinical aspects of the use of transvaginal mesh products for the treatment of pelvic organ prolapse and stress urinary incontinence and supports the subsequent Senate Community Affairs Reference Committee: Transvaginal Mesh 2018 recommendation: to stop the use of transvaginal mesh products that are solely used for the treatment of most pelvic organ prolapse.

Around 8 to 15% of transvaginal mesh procedures will have a complication, of which most are minor or temporary. However, some women have experienced severe complications, with some presenting with complications several years after the procedure.

In December 2017, the Australian Therapeutic Goods Administration removed from the Australian Register of Therapeutic Goods mesh products that were solely used for the treatment of most pelvic organ prolapse (such as bladder, bowel or uterine prolapse) via transvaginal implantation.

The statewide Pelvic Mesh Clinic is provided as part of RAH Gynaecology and RAH Urology departments, providing comprehensive health care for women experiencing minor or major complications related to pelvic mesh implants.

Further information and resources

The following information has been produced by the Australian Commission of Safety and Quality in Health Care: